Second Line Treatment With Nal-IRI and S1 in Pancreatic Cancer
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
To determine the optimal second line treatment strategy in patients with metastatic
pancreatic cancer who underwent a therapy with gemcitabine.
Phase:
Phase 2
Details
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborators:
Isala Maastricht University Medical Center Medical University of Vienna Odense University Hospital Odense University Hospital, Denmark UMC Utrecht University Hospital Verona, Italy Vall de Hebron, Barcelona, Spain